Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

HSDT vs PHIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HSDT Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

HSDT Overall Winner 6-Pillar Tally: HSDT 4 – 1 PHIO (1 Tie) Matrix Metrics: HSDT 7 – 3 PHIO

As of Nov 20, 2026, Solana Company (HSDT) is the stronger overall head-to-head candidate over Phio Pharmaceuticals Corp. (PHIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HSDT carries a Unified Composite Score of 47.2/100 (HOLD) at $1.49 (N/M Forward P/E, -1557.5% operating margin), whereas PHIO carries 41.2/100 (SELL) at $0.66 (0.3x Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: HSDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.3); meanwhile PHIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HSDT vs PHIO
HSDT NASDAQ Head-to-Head Winner
Solana Company Class A Common Stock (DE)
Electromedical & Electrotherapeutic Apparatus
$1.49
-10.24% 1D
Market Cap $104.4M
TTM Revenue $271M
Forward P/E N/M
Beta / 30D Vol 2.22β · 60% Vol
Unified Composite Score
47.2 / 100 HOLD
Tech 25.0 Fund 58.0 Flow 68.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.0%), weak momentum, RSI 24
RSI-14: 24.3 · SMA20: $1.92 · SMA50: $2.29
PHIO NASDAQ
Phio Pharmaceuticals Corp. Common Stock
Pharmaceutical Preparations
$0.66
-8.25% 1D
Market Cap $8.5M
TTM Revenue N/A
Forward P/E 0.3x
Beta / 30D Vol 1.07β · 57% Vol
Unified Composite Score
41.2 / 100 SELL
Tech 25.0 Fund 46.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.5%), weak momentum, RSI 23
RSI-14: 22.7 · SMA20: $0.81 · SMA50: $0.91

6-Pillar Scorecard Institutional Category Breakdown (HSDT 4 – 1 PHIO)

Columns: Metric · HSDT · PHIO
1. Valuation Multiples HSDT
Forward P/E N/M 0.3x
Trailing P/E 0.0x 0.3x
PEG Ratio N/M N/M
EV / Revenue 0.4x N/M
2. Growth & Scale HSDT
Revenue Growth (YoY) +382.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $271M N/A
Market Cap $104.4M $8.5M
3. Profitability & Quality HSDT
Gross Margin 92.8% N/A
Operating Margin -1557.5% 0.0%
Net Profit Margin 2040.4% 0.0%
Return on Equity (ROE) 52.8% -159.0%
4. Balance Sheet & Cash Flow HSDT
Cash Generation (TTM) -$4.21B EBITDA -$11M
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.38 Book/Sh · 52.8% ROE $0.72 Book/Sh · -159.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PHIO
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 540.7% (85th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Asset Management Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HSDT (7) vs PHIO (3)
Institutional Metric HSDT PHIO Criterion Row Edge
Market Capitalization
Scale
$104.4M $8.5M Larger Scale HSDT
Trailing P/E Ratio
Valuation
0.0x 0.3x Lower Multiple HSDT
Forward P/E Ratio
Valuation
N/M 0.3x Lower Multiple PHIO
Revenue Growth (YoY)
Growth
+382.1% +0.0% Higher Growth HSDT
Operating Margin (TTM)
Profitability
-1557.5% 0.0% Higher Margin PHIO
Net Profit Margin
Profitability
2040.4% 0.0% Higher Margin HSDT
Return on Equity (ROE)
Capital Efficiency
52.8% -159.0% Higher ROE HSDT
52-Week Range Position
Momentum
10% ($1–$4) 1% ($1–$2) Stronger Trend HSDT
Beta / 30D Volatility
Risk Regime
2.22β · 60% Vol 1.07β · 57% Vol Lower Realized Risk PHIO
Unified Institutional Score
Composite Signal
47.2 / 100 (HOLD) 41.2 / 100 (SELL) Higher Composite HSDT
Trailing 12M Revenue (USD)
Operating Scale
$271M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
92.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$4.21B EBITDA ($4.38 Book/Sh · 52.8% ROE) -$11M ($0.72 Book/Sh · -159.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PHIO +9.26 pp
HSDT: -34.07% · PHIO: -24.81%
3M Horizon HSDT +12.28 pp
HSDT: -31.65% · PHIO: -43.93%
6M Horizon HSDT +4.89 pp
HSDT: -34.93% · PHIO: -39.82%
1Y Horizon PHIO +12.85 pp
HSDT: -60.37% · PHIO: -47.52%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period HSDT Revenue PHIO Revenue HSDT Op. Margin PHIO Op. Margin Margin Leader
FY2018 $0M $0M -5580.5% -5336.2% PHIO
FY2019 $0M $0M -1604.0% -42795.2% HSDT
FY2020 $0M N/A -2176.4% N/A HSDT
FY2021 $0M N/A -3679.9% N/A HSDT
FY2022 $0M N/A -1994.3% N/A HSDT
FY2023 $0M N/A -2054.2% N/A HSDT
FY2024 $0M N/A -2673.7% N/A HSDT
FY2025 $0M N/A -44496.4% N/A HSDT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HSDT BREAKDOWN
43d in phase · OBV DISTRIBUTION
Current IV 540.7%
IV Percentile 85th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact HSDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PHIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PHIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HSDT Moat Profile High-Margin Pricing Power Moat
Asset Management Operator
Competes within the Asset Management value chain with $104.4M market capitalization and -1557.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PHIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $8.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HSDT vs PHIO Key Questions & Quantitative Answers

As of Nov 20, 2026, Solana Company (HSDT) is the stronger overall head-to-head candidate over Phio Pharmaceuticals Corp. (PHIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HSDT carries a Unified Composite Score of 47.2/100 (HOLD) at $1.49 (N/M Forward P/E, -1557.5% operating margin), whereas PHIO carries 41.2/100 (SELL) at $0.66 (0.3x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: HSDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.3); meanwhile PHIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HSDT leads the Growth & Scale pillar: HSDT posts +382.1% YoY revenue growth and +0.0% YoY earnings growth on $271M TTM revenue (92.8% gross margin, -1557.5% operating margin), compared with PHIO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), HSDT cumulative revenue shifted N/A while PHIO shifted N/A. In operating R&D and SG&A reinvestment, HSDT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PHIO.

HSDT screens cheaper on headline valuation multiples. HSDT trades at N/M Forward P/E, 0.0x Trailing P/E, N/M PEG, and 0.4x EV/Revenue (unreported EBITDA margin), whereas PHIO trades at 0.3x Forward P/E, 0.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HSDT (52.8% ROE) versus PHIO (-159.0% ROE) capital efficiency.

In options market volatility and institutional positioning, HSDT carries 540.7% implied volatility (85th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.22β · 60% Vol realized risk). By comparison, PHIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.07β · 57% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.